FDA Solicits Databases To Track Infrequent, Rare Drug AEs
This article was originally published in The Tan Sheet
Executive Summary
FDA is looking to establish cooperative agreements for databases that track drug adverse events in the U.S., a request for funding applications published in the Federal Register April 4 states.